# Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers

> **NCT01074996** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Hospital of the Chinese Academy of Military Medical Sciences** · enrollment: 92 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** S-1
- **DRUG:** S-1 plus Leucovorin

## Key facts

- **NCT ID:** NCT01074996
- **Lead sponsor:** The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-02
- **Primary completion:** 2013-10
- **Final completion:** 2014-07
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2014-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074996, "Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01074996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*